Researchers create tool to help unravel secrets of cancer

Using novel methods, scientists have identified biological signatures in cancer cells that can be traced back to the original cancer gene.

Livia Eberlin is the lead researcher of a project examining the biological signatures in cancer cells.
Linda A. Cicero/Stanford News Service

An interdisciplinary team of chemists, oncologists and one statistician at Stanford has taken the first step toward developing a technique that can identify the origin of certain types of cancer — a potential boon to doctors prescribing therapies for their patients.

The researchers’ findings were published July 3 in the Proceedings of the National Academy of Sciences.

 “The same cancer can occur because of different genes, but in certain cases the aggressiveness and the type of treatment actually depend a lot on what oncogene caused that cancer,” said Livia Eberlin, PhD, a postdoctoral scholar in chemistry and lead author of the paper.

An oncogene is a normal gene that has mutated, causing cells to become cancerous. In this study, the team members looked at one that is related to lymphoma and responsible for approximately half of all human cancers. They wanted to find a biological signature that would trace the mutating cancer cells back to the original oncogene.

“When cancer takes place, the cell loves to gobble up glucose — that’s a sugar — and glutamine,” said Richard Zare, PhD, professor of chemistry and senior author of the paper, who served as an adviser to Eberlin. “It takes those and makes different lipids — different fatty molecules than what it normally makes.”

Diagnostic and prognostic

Using a statistical method from co-author Robert Tibshirani, PhD, professor of health research and policy and of statistics, the team was able to identify not just one but 86 lipids that can be traced back to an oncogene.

“It’s not just diagnostic,” Eberlin said. “It gives extra information that could be prognostic.”

This is a tool to understand the nature of how cancer progresses.

Depending on the bio-signature of the cancer cells, physicians will have a better idea of the aggressiveness of a patient’s cancer. In the future, this research may lead to a better knowledge of cancer in general.

“The next step is to use this as a way to figure out the causal mechanism,” said Dean Felsher, MD, PhD, professor of medicine and of pathology and a co-author of the paper. “Though the connection between the cancer cells and their origin is clear, the actual cause of cancer — the biological trigger that pushes cancer to progress — is still mysterious.

As Zare mused, “How does cancer really work? This is a tool to understand the nature of how cancer progresses.”

Other co-authors of the paper are Alice Fan, assistant professor of medicine, and postdoctoral scholars Meital Gabay, PhD, and Arvin Gouw, PhD.

The research was supported by grants from the National Science Foundation, the National Institutes of Health and the Air Force Office of Scientific Research, as well as by a Stanford Hospital & Clinics Cancer Innovation Fund award. 



Stanford Medicine integrates research, medical education and health care at its three institutions - Stanford University School of Medicine, Stanford Health Care (formerly Stanford Hospital & Clinics), and Lucile Packard Children's Hospital Stanford. For more information, please visit the Office of Communication & Public Affairs site at http://mednews.stanford.edu.

Leading the Biomedical Revolution

We are in the middle of a biomedical revolution more profound and far-reaching than the industrial and digital revolutions that made it possible.

A Legacy of Innovation

Stanford Medicine's unrivaled atmosphere of breakthrough thinking and interdisciplinary collaboration has fueled a long history of achievements.